Annalicia Vaughan

Annalicia Vaughan

Auto-generated profile, based on publicly available information

Annalicia Vaughan

Centre for Inflammation, Centenary Institute, Sydney, NSW, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
PCPeter Collins
Peter Collins
IYIan A. Yang
Ian A. Yang
YCYuan-Chin Chang
Yuan-Chin Chang
AVAnnalicia Vaughan
Annalicia Vaughan
Chronic obstructive pulmonary disease (COPD) primarily affects the lungs but due to the accompanying chronic systematic inflammation and the symptoms associated with the disease there are many extrapulmonary effects which include complex physical and metabolic adaptations. These changes have been associated with reduced exercise capacity, increased nutritional requirements, altered metabolic processes and compromised nutritional intake. As a result, nutritional depletion in COPD is multi-faceted and can involve imbalances of energy (weight loss), protein (sarcopenia), and periods of markedly increased inflammation (pulmonary cachexia) which can increase nutritional losses. As a result, depletion of both fat-mass (FM) and fat-free mass (FFM) can occur. There is good evidence that nutritional support, in the form of oral nutritional supplements (ONS), can overcome energy and protein imbalances resulting in improved nutritional status and functional capacity. However, in order to treat the aetiology of sarcopenia, frailty and cachexia, it is likely that targeted multi-modal interventions are required to address energy and protein imbalance, specific nutrient deficiencies, reduced androgens and targeted exercise training. Furthermore, interventions taking a disease-course approach, are likely to hold the key to effectively managing the common and costly problem of nutritional depletion in COPD.

1 November 2014
Verified
Journal Article
Open access
PDF file
JSJanet G. Shaw
Janet G. Shaw
AVAnnalicia Vaughan
Annalicia Vaughan
ADAnnette G. Dent
Annette G. Dent
POPhoebe E. O’hare
Phoebe E. O’hare
FGFelicia Goh
Felicia Goh
IYIan A. Yang
Ian A. Yang
Biomarkers of progression of chronic obstructive pulmonary disease (COPD)

8 February 2024 in Gut
Verified
Journal Article
Closed access
PDF file
Kurtis Francis BuddenKurtis Francis Budden
Kurtis Francis Budden
SSShakti Shukla
Shakti Shukla
KBKate L Bowerman
Kate L Bowerman
AVAnnalicia Vaughan
Annalicia Vaughan
SGShaan L Gellatly
Shaan L Gellatly
PHPhilip M. Hansbro
Philip M. Hansbro
Objective: Chronic obstructive pulmonary disease (COPD) is a major cause of global illness and death, most commonly caused by cigarette smoke. The mechanisms of pathogenesis remain poorly understood, limiting the development of effective therapies. The gastrointestinal microbiome has been implicated in chronic lung diseases via the gut-lung axis, but its role is unclear. Design: Using an in vivo mouse model of cigarette smoke (CS)-induced COPD and faecal microbial transfer (FMT), we characterised the faecal microbiota using metagenomics, proteomics and metabolomics. Findings were correlated with airway and systemic inflammation, lung and gut histopathology and lung function. Complex carbohydrates were assessed in mice using a high resistant starch diet, and in 16 patients with COPD using a randomised, double-blind, placebo-controlled pilot study of inulin supplementation. Results: FMT alleviated hallmark features of COPD (inflammation, alveolar destruction, impaired lung function), gastrointestinal pathology and systemic immune changes. Protective effects were additive to smoking cessation, and transfer of CS-associated microbiota after antibiotic-induced microbiome depletion was sufficient to increase lung inflammation while suppressing colonic immunity in the absence of CS exposure. Disease features correlated with the relative abundance of Muribaculaceae, Desulfovibrionaceae and Lachnospiraceae family members. Proteomics and metabolomics identified downregulation of glucose and starch metabolism in CS-associated microbiota, and supplementation of mice or human patients with complex carbohydrates improved disease outcomes. Conclusion: The gut microbiome contributes to COPD pathogenesis and can be targeted therapeutically.

1 October 2019 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
AVAnnalicia Vaughan
Annalicia Vaughan
ZFZoe A. Frazer
Zoe A. Frazer
PHPhilip M. Hansbro
Philip M. Hansbro
IYIan A. Yang
Ian A. Yang
Current management strategies for chronic obstructive pulmonary disease (COPD) incorporate a step-wise, multidisciplinary approach to effectively manage patient symptoms and prevent disease progression. However, there has been limited advancement in therapies to address the underlying cause of COPD pathogenesis. Recent research has established the link between the lungs and the gut—the gut-lung axis -and the gut microbiome is a major component. The gut microbiome is likely perturbed in COPD, contributing to chronic inflammation. Diet is a readily modifiable factor and the diet of COPD patients is often deficient in nutrients such as fibre. The metabolism of dietary fibre by gut microbiomes produces anti-inflammatory short chain fatty acid (SCFAs), which could protect against inflammation in the lungs. By addressing the ‘fibre gap’ in the diet of COPD patients, this targeted dietary intervention may reduce inflammation, both systemically and in the airways, and value-add to the paradigm shift in respiratory medicine, from reactive to personalised and participatory medicine.

1 June 2017 in Atmospheric Environment
Verified
Journal Article
Closed access
Stevanovic SvetlanaStevanovic Svetlana
Stevanovic Svetlana
AVA. Vaughan
A. Vaughan
FHF. Hedayat
F. Hedayat
FSF. Salimi
F. Salimi
Md Mostafizur RahmanMd Mostafizur Rahman
Md Mostafizur Rahman
ZRZoran Ristovski
Zoran Ristovski

1 March 2019 in Environmental Research
Verified
Journal Article
Closed access
AVAnnalicia Vaughan
Annalicia Vaughan
Stevanovic SvetlanaStevanovic Svetlana
Stevanovic Svetlana
MJMohammad Jafari
Mohammad Jafari
Md Mostafizur RahmanMd Mostafizur Rahman
Md Mostafizur Rahman
RBRayleen V. Bowman
Rayleen V. Bowman
IYIan A. Yang
Ian A. Yang